Monday, October 1, 2007

Buy Propecia

PROPECIA®(finasteride)Tablets, 1 mg


PROPECIA* (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II
5?-reductase, an intracellular enzyme that converts the androgen testosterone into
5?-dihydrotestosterone (DHT).
Finasteride is 4-azaandrost-1-ene-17-carboxamide,N-(1,1-dimethylethyl)-3-oxo-,(5?,17?)-. The
empirical formula of finasteride is C23H36N2O2 and its molecular weight is 372.55.


PROPECIA is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN
ONLY. Safety and efficacy were demonstrated in men between 18 to 41 years of age with mild to
moderate hair loss of the vertex and anterior mid-scalp area (see CLINICAL PHARMACOLOGY, Clinical
Efficacy in bitemporal recession has not been established.
PROPECIA is not indicated in women (see CLINICAL PHARMACOLOGY, Clinical Studies and
PROPECIA is not indicated in children (see PRECAUTIONS, Pediatric Use).


In clinical studies, single doses of finasteride up to 400 mg and multiple doses of finasteride up to
80 mg/day for three months did not result in adverse reactions. Until further experience is obtained, no
specific treatment for an overdose with finasteride can be recommended.
Significant lethality was observed in male and female mice at single oral doses of 1500 mg/m2
(500 mg/kg) and in female and male rats at single oral doses of 2360 mg/m2 (400 mg/kg) and
5900 mg/m2 (1000 mg/kg), respectively.


The recommended dosage is 1 mg orally once a day.
PROPECIA may be administered with or without meals.
In general, daily use for three months or more is necessary before benefit is observed. Continued use
is recommended to sustain benefit, which should be re-evaluated periodically. Withdrawal of treatment
leads to reversal of effect within 12 months.


Finasteride is a competitive and specific inhibitor of Type II 5?-reductase, an intracellular enzyme that
converts the androgen testosterone into DHT. Two distinct isozymes are found in mice, rats, monkeys,
and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and
developmental stages. In humans, Type I 5?-reductase is predominant in the sebaceous glands of most
regions of skin, including scalp, and liver. Type I 5?-reductase is responsible for approximately one-third
of circulating DHT. The Type II 5?-reductase isozyme is primarily found in prostate, seminal vesicles,
epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.
In humans, the mechanism of action of finasteride is based on its preferential inhibition of the Type II
isozyme. Using native tissues (scalp and prostate), in vitro binding studies examining the potential of
finasteride to inhibit either isozyme revealed a 100-fold selectivity for the human Type II 5?-reductase
over Type I isozyme (IC50=500 and 4.2 nM for Type I and II, respectively). For both isozymes, the
inhibition by finasteride is accompanied by reduction of the inhibitor to dihydrofinasteride and adduct
formation with NADP+. The turnover for the enzyme complex is slow (t1/2 approximately 30 days for the
Type II enzyme complex and 14 days for the Type I complex).
Finasteride has no affinity for the androgen receptor and has no androgenic, antiandrogenic,
estrogenic, antiestrogenic, or progestational effects. Inhibition of Type II 5?-reductase blocks the
peripheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT


PROPECIA is contraindicated in the following:
Pregnancy. Finasteride use is contraindicated in women when they are or may potentially be
pregnant. Because of the ability of Type II 5?-reductase inhibitors to inhibit the conversion of testosterone
to DHT, finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant
woman who receives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while
taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. (See
for Patients and Pregnancy.) In female rats, low doses of finasteride administered during pregnancy have
produced abnormalities of the external genitalia in male offspring.
Hypersensitivity to any component of this medication.


PROPECIA is not indicated for use in pediatric patients (see INDICATIONS AND USAGE; and
PRECAUTIONS, Pediatric Use) or women (see also WARNINGS, EXPOSURE OF WOMEN - RISK TO
MALE FETUS; PRECAUTIONS, Information for Patients and Pregnancy; and HOW SUPPLIED, Storage
and Handling).
Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may
potentially be pregnant because of the possibility of absorption of finasteride and the subsequent
potential risk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active
PROPECIA® (Finasteride) Tablets, 1 mg 9636001
ingredient during normal handling, provided that the tablets have not been broken or crushed. (See also
CONTRAINDICATIONS; PRECAUTIONS, Information for Patients and Pregnancy; and HOW
SUPPLIED, Storage and Handling.)


Caution should be used in the administration of PROPECIA in patients with liver function
abnormalities, as finasteride is metabolized extensively in the liver.
Information for Patients
Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may
potentially be pregnant because of the possibility of absorption of finasteride and the subsequent
potential risk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active
ingredient during normal handling, provided that the tablets have not been broken or crushed. (See also
PRECAUTIONS, Pregnancy; and HOW SUPPLIED, Storage and Handling.)
Physicians should instruct their patients to promptly report any changes in their breasts such as
lumps, pain or nipple discharge. Breast changes including breast enlargement, tenderness and neoplasm
have been reported (see ADVERSE REACTIONS).
See also Patient Package Insert.
Physicians should instruct their patients to read the patient package insert before starting therapy with
PROPECIA and to read it again each time the prescription is renewed so that they are aware of current
information for patients regarding PROPECIA.
Drug/Laboratory Test Interactions
Finasteride had no effect on circulating levels of cortisol, thyroid-stimulating hormone, or thyroxine, nor
did it affect the plasma lipid profile (e.g., total cholesterol, low-density lipoproteins, high-density
lipoproteins and triglycerides) or bone mineral density. In studies with finasteride, no clinically meaningful
changes in luteinizing hormone (LH), follicle-stimulating hormone (FSH) or prolactin were detected. In
healthy volunteers, treatment with finasteride did not alter the response of LH and FSH to gonadotropinreleasing
hormone indicating that the hypothalamic-pituitary-testicular axis was not affected.
In clinical studies with PROPECIA (finasteride, 1 mg) in men 18-41 years of age, the mean value of
serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.
Further, in clinical studies with PROSCAR (finasteride, 5 mg) when used in older men who have benign
prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%. These findings should be
taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride.
Drug Interactions
No drug interactions of clinical importance have been identified. Finasteride does not appear to affect
the cytochrome P450-linked drug-metabolizing enzyme system. Compounds that have been tested in
man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful
interactions were found.
Other concomitant therapy: Although specific interaction studies were not performed, finasteride
doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic
acid, ?-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants,
benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists,
HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and
quinolone anti-infectives without evidence of clinically significant adverse interactions.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No evidence of a tumorigenic effect was observed in a 24-month study in Sprague-Dawley rats
receiving doses of finasteride up to 160 mg/kg/day in males and 320 mg/kg/day in females. These doses
produced respective systemic exposure in rats of 888 and 2192 times those observed in man receiving
the recommended human dose of 1 mg/day. All exposure calculations were based on calculated
AUC(0-24 hr) for animals and mean AUC(0-24 hr) for man (0.05 ?g•hr/mL).

Thursday, May 3, 2007

Propecia Hair Loss Treatments

If there is one critical point that I stress with all of my hair replacement patients it is that Androgenetic Alopecia (Male or Female Pattern Baldness) is absolutely progressive. All of the most wonderful hair transplantation procedures that I perform today on my patients do not stop this progressive condition.


Consider the fact that after half of your hair has already fallen is when you even BEGIN to notice your hair thinning and seek hair loss treatment. The horse is long gone from the barn before you notice it is missing. In other words, hair loss is an insidious process that often goes unnoticed for a long, long time.


This is why I feel very strongly that hair loss treatment such as medical therapy is extremely important -- and the earlier you begin, the better chances you will have for hair replacement.

If you are experiencing male or female pattern baldness, it makes the best sense to use medical treatment in conjunction with your hair replacement surgery because the transplants will grow beautifully, but the non-transplanted hairs will continue to fall. Hair loss treatment to KEEP these surrounding hairs on your head while the transplants grow, will allow you to have even MORE hair -- without always having to continue to aggressively catch up with the progression. There are a variety of hair loss treatment options available at our Rhode Island, Massachusetts, and New Hampshire offices.


PROPECIA® (finasteride 1mg)

PROPECIA® (finasteride 1mg)

Propecia® is the first and only FDA-approved hair replacement oral medication to treat Male Pattern Hair Loss. Its mechanism of action is to decrease the amount of Dihydrotestosterone (DHT) that is both in your bloodstream as well as in the skin near your hair follicles.

Propecia® works 83 percent of the time to stop further progression of hair loss and it works 66 percent of the time as a hair replacement mechanism. This hair loss treatment stops progression in the crown and forward along the central part of your head. It regrows the hair in the crown. It is not particularly effective, though, in the frontal receded areas.


Recent study data show that there are 277 hairs per 1-inch circle more on the heads of people taking Propecia as compared to those taking a placebo at the end of five years. That is A LOT more hair, making this hair loss treatment very effective!

It takes about three months of usage before you will notice less hair falling and approximately six months before I shall notice hair replacement.


I want my patients to use the hair loss treatment Propecia® for at least 18 months because I feel that it truly takes this long to determine its effectiveness. If you stop it sooner, I don't think you will have given it adequate time to see how well it could be working for you.

The pill is taken once a day -- with or without food. There are no known drug interactions.

Everybody is worried about the supposed side effects of this medication. Well, here are the facts. There are only three known side effects that have been observed during the study of thousands of men. They occur in 1/2 of 1 percent of people: decreased hardness of an erection, decreased libido, and decreased volume of ejaculate. That's it. And, again, they occur in only 1/2 of 1 percent of individuals taking this hair loss treatment. The recently released 5-year data show these to occur even less than this small percentage.


More good news about potential side effects of this hair loss treatment is that if a man were to be among the unlucky one half percent, and he kept on taking the medication for another couple of weeks, then 58 percent of the time he would revert back to normal (because the body adjusts to the drug). A full one hundred percent will go back to normal if they stop the medication. So, there are no long-term side effects to worry about. Don't let inaccurate scare tactics dissuade you from using this great medication. This is a long-term therapy that should not be stopped. The hair replacement medication Propecia is available at our Massachusetts and Rhode Island facilities.


Rogaine (minoxidil 2% and 5%)

Rogaine Topical Solution was available for many years as a prescription medication. Today, however, this hair loss treatment can be purchased without a doctor's prescription.

It is a drug that is applied to your scalp twice a day. I have my hair replacement patients shampoo their hair, towel dry it, and then apply the Rogaine Solution using the dropper applicator. I suggest this applicator because it gets the medication onto the skin where it needs to be, rather than in the hair itself. The hair loss treatment should then be spread over the entire top of the scalp.

It takes at least four months to notice less hair falling out and at least seven months for me to begin to observe hair replacement. The regrowth is usually vellus (fine, short hairs). Rogaine must be used two times per day in order for it to be an effective form of hair loss treatment.


The main side effects of Rogaine are dermatological and they occur approximately 2 percent of the time. This is a long-term hair loss treatment that should not be stopped, and is available at our Rhode Island and Massachusetts locations.